Skin Care Using Heparinoid Creams for Long-Term Treatment with Oxybutynin Transdermal Patches without Skin Irritation in Elderly OAB Patients

2018 ◽  
Vol 2 (1) ◽  
pp. 01-03
Author(s):  
Luke Jackson ◽  
Jonathan Noah ◽  
Miguel Seth ◽  
Collin Jared
Keyword(s):  
Overactive Bladder ◽  
Adverse Reactions ◽  
Skin Irritation ◽  
Transepidermal Water Loss ◽  
Skin Hydration ◽  
Transdermal Patch ◽  
Transdermal Patches ◽  
Bladder Symptom ◽  
Overactive Bladder Symptom Score

Background: Overactive bladder is an age-related urologic disease. An oxybutynin transdermal patch is used to treat overactive bladder; however, long-term use is not advised because of potential adverse reactions at the site of application. The present study aimed to investigate the advantages of administering a combination of heparinoid cream and oxybutynin transdermal patch treatment for overactive bladder in elderly patients. Methods: Eight patients (>65 years of age) with overactive bladder were included. The heparinoid cream was applied topically for 1 week, and skin hydration and transepidermal water loss were quantified before and after application. Thereafter, patients were treated with a combination of an oxybutynin transdermal patch and a heparinoid cream for 12 weeks, and the sites of application were monitored for adverse reactions. Clinical effects of the combinatorial treatment were assessed based on the overactive bladder symptom score. Results: Application of the heparinoid cream did not decrease transepidermal water loss, but increased skin hydration and improved dryness. Oxybutynin transdermal patch therapy was not interrupted because no skin irritation was observed at the site of application for 12 weeks, and the overactive bladder symptom score decreased significantly (p<0.05). Conclusions: Combination treatment with an oxybutynin transdermal patch and a heparinoid cream improved treatment outcomes, suggesting that skin hydration with heparinoid cream is a promising treatment method to ensure appropriate use of oxybutynin transdermal patches in elderly patients with overactive bladders.

scholarly journals Combination of oxybutynin transdermal patch and heparinoid cream for long-term treatment of overactive bladder in elderly patients

2018 ◽  
Vol 6 (1) ◽  
pp. 1
Author(s):  
Yoshihito Murakami ◽  
Hiroshi Nagae ◽  
Naomi Maehori ◽  
Hidehisa Sekijima ◽  
Kazuya Ooi
Keyword(s):  
Overactive Bladder ◽  
Elderly Patients ◽  
Term Treatment ◽  
Transdermal Patch ◽  
Long Term Treatment

Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score

Urology ◽  
2006 ◽  
Vol 68 (2) ◽  
pp. 318-323 ◽  
Author(s):  
Yukio Homma ◽  
Masaki Yoshida ◽  
Narihito Seki ◽  
Osamu Yokoyama ◽  
Hidehiro Kakizaki ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Symptom Score ◽  
Assessment Tool ◽  
Symptom Assessment ◽  
Overactive Bladder Syndrome ◽  
Bladder Symptom ◽  
Overactive Bladder Symptom Score

scholarly journals Evaluation of Lower Urinary Tract Symptoms (LUTS): Severity Score and Symptom Association

2019 ◽  
Vol 4 (2) ◽  
pp. 684-687
Author(s):  
Tarun Pradhan ◽  
Baburam Dixit Thapa ◽  
Pritha Basnet ◽  
Surya Prasad Rimal ◽  
Tulasha Basnet ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Overactive Bladder ◽  
Lower Urinary Tract Symptoms ◽  
Urge Incontinence ◽  
Lower Urinary Tract ◽  
Time Frequency ◽  
Urinary Tract Symptoms ◽  
Bladder Symptom ◽  
Overactive Bladder Symptom Score ◽  
Lower Urinary

Introduction: Lower urinary tract symptoms (LUTS) is a group of symptoms relating to stages of micturation such as storage symptoms, voiding dysfunction and post micturation dysfunction. Overactive bladder symptom score (OABSS) is a questionnaires with scores which helps in evaluating the severity of symptoms. Objectives To find the incidence of women visiting with LUTS and to evaluate storage symptoms in LUTS (urgency, urge incontinence, frequency) using OABSS (overactive bladder symptom score) questionnaires. Methodology This is a prospective study done from February 2016 to February 2017. Patients visiting Department of Obstetrics and Gynaecology with lower urinary tract symptoms (LUTS) were enrolled in the study after informed consent. Patients were assessed for types of LUTS and data were filled in the performa. If patients had urgency, urge incontinence, increased day time frequency, then the patients were explained and asked overactive bladder symptom score questionnaire (OABSS) and noted. Patients were then examined for pelvic floor dysfunction and neurological abnormalities for identifying association with the symptoms. Statistical analysis was done using SPSS 11.5. Results Fifty-seven patients were enrolled with lower urinary tract symptoms (LUTS) during study period. Forty-six patients had overactive bladder symptoms (OABS). LUTS were found in age ranging from 21 to 80 years. Majority of patients visiting out-patient department with LUTS were found to have urgency, urge incontinence, increased day time frequency, nocturia. Patients with urgency and urge incontinence showed significant correlation with increasing likert score of OABSS (p<0.05). But the increased day time frequency did not show any correlation with increasing score. The score showed significant correlation with combination of symptoms (urgency, urge incontinence and increased frequency) than patients presenting with single symptom. Conclusion Diagnosis of LUTS with valid assessment tools and treatment benefits patients with chronic urinary symptoms and also helps clinicians to further re-assess the treatment.

Responsiveness and Minimal Clinically Important Change in Overactive Bladder Symptom Score

Urology ◽  
2011 ◽  
Vol 78 (4) ◽  
pp. 768-773 ◽  
Author(s):  
Momokazu Gotoh ◽  
Yukio Homma ◽  
Osamu Yokoyama ◽  
Osamu Nishizawa
Keyword(s):  
Overactive Bladder ◽  
Symptom Score ◽  
Important Change ◽  
Bladder Symptom ◽  
Clinically Important Change ◽  
Overactive Bladder Symptom Score

Reliability and validity of the overactive bladder symptom score in spanish (OABSS-S)

2012 ◽  
Vol 31 (5) ◽  
pp. 664-668 ◽  
Author(s):  
Aaron C. Weinberg ◽  
Gary H. Brandeis ◽  
John Bruyere ◽  
Johnson F. Tsui ◽  
Jeffrey P. Weiss ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Symptom Score ◽  
Reliability And Validity ◽  
Bladder Symptom ◽  
Overactive Bladder Symptom Score

Acute Dermal Irritation, Sensitization, and Acute Toxicity Studies of a Transdermal Patch for Prophylaxis Against (±) Anatoxin-A Poisoning

2013 ◽  
Vol 32 (4) ◽  
pp. 308-313 ◽  
Author(s):  
Subham Banerjee ◽  
Pronobesh Chattopadhyay ◽  
Animesh Ghosh ◽  
Manash Pratim Pathak ◽  
Shweta Singh ◽  
...  
Keyword(s):  
Guinea Pigs ◽  
Day Treatment ◽  
Skin Irritation ◽  
Positive Control ◽  
Transdermal Patch ◽  
Dermal Toxicity ◽  
Placebo Patch ◽  
Dermal Irritation ◽  
Transdermal Patches ◽  
Skin Irritation Test

The skin irritating, sensitizing, and acute dermal toxicity potential of a novel combinational prophylactic transdermal patch, mainly composed of eserine and pralidoxime chloride as active pharmaceutical ingredients, against (±) anatoxin-a poisoning were investigated in rabbits, guinea pigs, and rats in compliance with the Organisation for Economic Cooperation and Development guidelines. In primary skin irritation test, rabbits were dermally attached with the therapeutically active transdermal patch or with a placebo patch for 72 hours. The transdermal patches did not induce any adverse reactions such as erythema and edema on intact skin sites. The active patch was classified as a practically nonirritating material based on the score in the primary irritation index. In the Buehler test, guinea pigs were sensitized by the active or placebo transdermal patches attached for 24 hours. The patches did not induce any sensitization reactions in contrast to a severe sensitization reaction that occurred in the positive control. Therefore, the active patch and placebo patch were both graded as weak in sensitization score and rate. Acute dermal toxicity test in rats did not produce any overt signs of toxicity following a 14-day treatment period. Taken together, these findings suggest that the transdermal patch does not cause skin irritation, skin sensitization, or dermal toxic effects following dermal application.

Sign in / Sign up

Export Citation Format

Share Document